Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Developing a Potential New Treatment for Chronic PTSD: Ketamine Combined with Written Exposure Therapy

April 02, 2025 at 08:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

New York, April 02, 2025 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) invites the public to a free webinar, “Developing a Potential New Treatment for Chronic PTSD: Ketamine Combined with Written Exposure Therapy” on Tuesday, April 8, 2025, at 2:00 pm ET. Adriana Feder, M.D., Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai will be the guest speaker, and the session will be hosted by Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation and host of the Emmy® nominated television series Healthy Minds.

Register Now to hear Dr. Feder’s latest research advancements on PTSD treatments.

Individuals with chronic post-traumatic stress disorder (PTSD) need effective and tolerable treatments, especially those with more severe and persistent symptoms.
Dr. Feder's research focuses on the development of novel treatment interventions for PTSD and related disorders. Her research significantly contributed to the development of ketamine as a treatment for PTSD.

In this webinar, Dr. Feder will present results of the first open-label clinical trial combining a course of repeated ketamine infusions with a brief, evidence-based psychotherapy for PTSD called written exposure therapy (WET). This pilot trial will be explained in the context of prior ketamine studies for PTSD.

About Brain & Behavior Research Foundation
The Brain & Behavior Research Foundation (BBRF) awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention. Since 1987, the Foundation has awarded more than $462 million to fund more than 5,600 leading scientists around the world. 100% of every dollar donated for research is invested in research. BBRF operating expenses are covered by separate foundation grants. BBRF is the producer of the Emmy® nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which aims to remove the stigma of mental illness and demonstrate that with help, there is hope.

Attachments

Myrna Manners
Brain & Behavior Research Foundation
(718) 986-7255
mmanners@mannersdotson.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

272.26

-0.39 (-0.14%)

AAPL

312.41

+1.41 (0.45%)

AMD

489.28

+7.23 (1.50%)

BAC

63.00

-0.25 (-0.40%)

GOOG

356.62

-3.51 (-0.97%)